



## **Milestone® Pharmaceuticals to Present at Upcoming Conferences**

August 19, 2025

MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference, to take place September 8 – 10, 2025, in New York.

A webcast of the H.C. Wainwright presentation will be available on September 9 at 12:00 PM EDT. The webcast will be available to watch [live](#) and a replay will be available for approximately 90-days following the presentation on the News & Events section of Milestone's website [www.milestonepharma.com](http://www.milestonepharma.com).

If you are interested in meeting with the Milestone team during the conference, please reach out to your Wells Fargo or H.C. Wainwright representative.

### **About Milestone Pharmaceuticals**

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.

### **Contact**

#### **Investor Relations**

Kevin Gardner, [kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)



Source: Milestone Pharmaceuticals Inc.